AXM Pharma, Inc (AXMP)

[vincent333]

This is real good news. Look at the revenue of $ 12.820.000!!!!!!!

AXM Pharma Appointed Exclusive Sales and Marketing Agent for Leading Pharmaceutical Product
Company Receives $12.8 Million in Purchase Orders From Local Distributors
Feb 8, 2007 8:00:00 AM
Copyright Business Wire 2007
DIAMOND BAR, Calif.--(BUSINESS WIRE)--

AXM Pharma Inc. (OTC: AXMP) a manufacturer of proprietary and generic pharmaceutical and nutraceutical products for the Chinese and other Asian markets, announced today that Brazil Wahsun Import & Export Ltd. has signed a ten-year agreement, under which AXM Pharma has been designated exclusive distributor for Sygen, a product which is produced by TRB Pharma of Brazil. Sygen measures pathological changes in the central nervous system and Parkinson's disease. AXM has entered into agreements with distributors from leading cities and provinces of Shanghai, Beijing, Guangdong, Jiangsu, Zhejiang and Shandong, to purchase a total quantity of 500,000 units, resulting in 2007 estimated revenue of $12,820,000.

"We are excited to receive commitments from leading distributors within the country for this product," said Wang Weishi, President and CEO of AXM Pharma. "Sygen has been extremely popular in international markets, and we are confident, based upon significant purchase orders from local distributors that it will be equally successful in China."

About AXM Pharma, Inc.

AXM Pharma, Inc., through its wholly owned subsidiary, AXM Pharma Shenyang, Inc. ("AXM Shenyang"), is a manufacturer of proprietary and generic pharmaceutical products, which include injectables, capsules, tablets, liquids and medicated skin products for export and domestic Chinese sales. AXM Shenyang is located in the City of Shenyang, in the Province of Liaoning, China. AXM Shenyang has an operating history of approximately 10 years. For additional information on AXM Pharma Inc., please visit http://www.axmpharma.com

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this news release include certain predictions and projections that may be considered forward-looking statements under securities law, including the statements regarding the Company's opportunities for future growth. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, obtaining regulatory approvals to market the Company's products, the uncertainties associated with distributing products in a developing country such as China, the availability of cash to meet near term requirements as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products and prices. With respect to AXM, except for the historical information contained herein, the matters discussed in this news release are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, AXM's extremely limited operating history, uncertainties related to the Company's access to additional capital, competition and dependence on key management.

Source: AXM Pharma Inc.